Correlation of serum levels of transforming growth factor with clinical, instrumental and laboratory markers of chronic heart failure with preserved left ventricular ejection fraction

Despite the presence of multiple biomarkers, no “gold standard” has been identified yet to serve as a reliable tool for pharmacotherapy effectiveness monitoring, early diagnosis, clinical outcome prognosis, and risk stratification of patients with chronic heart failure with preserved ejection fraction (HFpEF) of the left ventricle. Goal: The goal of the study was to investigate correlations of the levels of serum transforming growth factor b (TGF-b1) with clinical, instrumental, and laboratory markers of HFpEF. Materials and Methods. This clinical and pathophysiological study comprised 27 patients with HFpEF. Results. Correlation relationships were found for left ventricular myocardial mass, intraventricular septum thickness, serum level of tissue inhibitor of metalloproteinases-1 (TIMP-1), and serum level of matrix metalloproteinase 3 (MMP-3). Multiple regression analysis demonstrated the presence of a relationship between TGF-b1 and TIMP-1. The study revealed relationships of serum TGF-b level with clinical and instrumental indicators of myocardial hypertrophy and serum levels of TIMP-1 and MMP-3 in patients with HFpEF.